SLC18A2 and Dystonia: Studies on the treatment effects of the Vesicular Monoamine Transporter 2 (VMAT-2) inhibitors, valbenazine and deutetrabenazine, have shown that they are effective in treating tardive dyskinesia (Bhidayasiri et al., 2018; Solmi et al., 2018), but studies specifically addressing tardive dystonia are still lacking.